Dr. Guilcher is an associate professor of oncology and paediatrics at the University of Calgary. His clinical and research focus is hematopoietic cell transplantation (HCT) for non-malignant diseases. He also studies acute and late effects of oncologic and BMT therapies. He serves as the Vice Chair of the Board of Directors and Clinical Operations for the Sickle Transplant Alliance for Research and is the Chair Mentee of the HCT Late Effects Taskforce for the Children's Oncology Group.
He is Program Director for Pediatric Hematology/Oncology at the University of Calgary, volunteers in several roles with the Royal College of Physicians and Surgeons of Canada and teaches regularly in Mbarara, Uganda.
Hemoglobinopathies are increasingly prevalent in Canada, and curative therapies are of interest to families and care providers. New hematopoietic cell transplantation (HCT) approaches aim to minimize acute and late toxicities, reducing the risk of graft-versus-host disease and expanding donor options. This brief article aims to summarize my approach to HCT for transfusion dependent thalassemia and sickle cell disease.
Click here to read the 'Ask the Expert' article by Dr. Gregory Guilcher.